Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A2 | P23975 | 5/20 | 0.56 |
| ▸ | SLC6A4 | P31645 | 5/20 | 0.56 |
| ▸ | SLC6A3 | Q01959 | 5/20 | 0.56 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.56 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.44 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.44 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.44 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.44 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL18741903 | 0.98 | SLC6A2 (0.54) | SLC6A2SLC6A4SLC6A3KCNH2 | |
| SCHEMBL22918145 | 0.81 | SLC6A2 (0.50) | SLC6A2SLC6A4SLC6A3KCNH2CYP1A2 | |
| SCHEMBL4185356 | 0.81 | SLC6A2 (0.50) | SLC6A2SLC6A4SLC6A3KCNH2CYP1A2 | |
| Hydrochloric Acid SCHEMBL4184047 | 0.80 | SLC6A2 (0.49) | SLC6A2SLC6A4SLC6A3KCNH2 | |
| SCHEMBL22755235 | 0.79 | SLC6A2 (0.50) | SLC6A2SLC6A4SLC6A3KCNH2CYP1A2 | |
| SCHEMBL4711875 | 0.79 | SLC6A2 (0.55) | SLC6A2SLC6A4SLC6A3KCNH2CYP1A2 | |
| Hydrochloric Acid SCHEMBL11076402 | 0.78 | SLC6A2 (0.56) | SLC6A2SLC6A4SLC6A3KCNH2CYP1A2 | |
| SCHEMBL4187080 | 0.77 | SLC6A2 (0.55) | SLC6A2SLC6A4SLC6A3KCNH2 | |
| SCHEMBL4185566 | 0.77 | SLC6A2 (0.55) | SLC6A2SLC6A4SLC6A3KCNH2 | |
| SCHEMBL31284256 | 0.77 | SLC6A2 (0.55) | SLC6A2SLC6A4SLC6A3KCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1874298-A4 | METHODS AND COMPOSITIONS FOR PRODUCTION, FORMULATION AND USE OF 1-ARYL-3-AZABICYCLO[3,1,0]HEXANES | DOV PHARMACEUTICAL INC (US) | 2009-08-05 | — | — | EP | claimed |
| EP-1904059-A2 | METHOD FOR TREATING NERVOUS SYSTEM DISORDERS AND CONDITIONS | Wyeth a Corporation of the State of Delaware (US) | 2008-04-02 | — | — | EP | claimed |
| EP-1874298-A2 | METHODS AND COMPOSITIONS FOR PRODUCTION, FORMULATION AND USE OF 1-ARYL-3-AZABICYCLO[3,1,0]HEXANES | DOV Pharmaceutical Inc. (US) | 2008-01-09 | — | — | EP | claimed |
| WO-2007013936-A2 | METHOD FOR TREATING NERVOUS SYSTEM DISORDERS AND CONDITIONS | WYETH (US) | 2007-02-01 | — | — | WO | claimed |
| US-20070021488-A1 | Method for treating nervous system disorders and conditions | WYETH (US) | 2007-01-25 | — | — | US | claimed |
| WO-2006096810-A2 | METHODS AND COMPOSITIONS FOR PRODUCTION, FORMULATION AND USE OF 1-ARYL-3-AZABICYCLO[3.1.0] HEXANES | DOV PHARMACEUTICAL, INC. (US) | 2006-09-14 | — | — | WO | claimed |
| EP-4384165-A1 | MONOACYLGLYCEROL LIPASE MODULATORS FOR USE IN AUTISM SPECTRUM DISORDERS | Janssen Pharmaceutica NV (BE) | 2024-06-19 | — | — | EP | disclosed |
| WO-2023019094-A1 | MONOACYLGLYCEROL LIPASE MODULATORS FOR USE IN AUTISM SPECTRUM DISORDERS | JANSSEN PHARMACEUTICA NV (BE) | 2023-02-16 | — | — | WO | disclosed |
| EP-4103557-A1 | MONOACYLGLYCEROL LIPASE MODULATORS | Janssen Pharmaceutica NV (BE) | 2022-12-21 | — | — | EP | disclosed |
| EP-2167083-A2 | NOVEL 1- HETEROARYL-3-AZABICYCLOÝ3.1.0¨HEXANES, METHODS FOR THEIR PREPARATION AND THEIR USE AS MEDICAMENTS | DOV Pharmaceutical, Inc. (US) | 2010-03-31 | — | — | EP | disclosed |
| EP-1874298-A4 | METHODS AND COMPOSITIONS FOR PRODUCTION, FORMULATION AND USE OF 1-ARYL-3-AZABICYCLO[3,1,0]HEXANES | DOV PHARMACEUTICAL INC (US) | 2009-08-05 | — | — | EP | disclosed |
| WO-2008153937-A2 | NOVEL 1- HETEROARYL-3-AZABICYCLO[3.1.0]HEXANES, METHODS FOR THEIR PREPARATION AND THEIR USE AS MEDICAMENTS | DOV PHARMACEUTICAL, INC. (US) | 2008-12-18 | — | — | WO | disclosed |
| EP-1915148-A2 | METHODS AND COMPOSITIONS FOR THE TREATMENT OF NEUROPATHIES AND RELATED DISORDERS | DOV Pharmaceutical, Inc. (US) | 2008-04-30 | — | — | EP | disclosed |
| EP-1904059-A2 | METHOD FOR TREATING NERVOUS SYSTEM DISORDERS AND CONDITIONS | Wyeth a Corporation of the State of Delaware (US) | 2008-04-02 | — | — | EP | disclosed |
| EP-1874298-A2 | METHODS AND COMPOSITIONS FOR PRODUCTION, FORMULATION AND USE OF 1-ARYL-3-AZABICYCLO[3,1,0]HEXANES | DOV Pharmaceutical Inc. (US) | 2008-01-09 | — | — | EP | disclosed |
| WO-2007014264-A2 | METHODS AND COMPOSITIONS FOR THE TREATMENT OF NEUROPATHIES AND RELATED DISORDERS | DOV PHARMACEUTICAL, INC. (US) | 2007-02-01 | — | — | WO | disclosed |
| WO-2007013936-A2 | METHOD FOR TREATING NERVOUS SYSTEM DISORDERS AND CONDITIONS | WYETH (US) | 2007-02-01 | — | — | WO | disclosed |
| US-20070021488-A1 | Method for treating nervous system disorders and conditions | WYETH (US) | 2007-01-25 | — | — | US | disclosed |
| WO-2006096810-A2 | METHODS AND COMPOSITIONS FOR PRODUCTION, FORMULATION AND USE OF 1-ARYL-3-AZABICYCLO[3.1.0] HEXANES | DOV PHARMACEUTICAL, INC. (US) | 2006-09-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070021488-A1 | Method for treating nervous system disorders and conditions | AVPR1B, AVPR2, AVPR1A | SLC6A2 33/4885SLC6A4 145/4885SLC6A3 100/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.